Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Winfred C Wang"'
Autor:
Russell E. Ware, Rathi V. Iyer, Bruce W. Thompson, Phillip Seaman, Scott T. Miller, Winfred C. Wang, Beatrice Files, Ofelia A. Alvarez, Jeffrey D. Lebensburger, Zhaoyu Luo, Courtney D. Thornburg, Ram Kalpatthi
Publikováno v:
Blood. 120:4304-4310
The Pediatric Hydroxyurea Phase 3 Clinical Trial (BABY HUG) was a phase 3 multicenter, randomized, double-blind, placebo-controlled clinical trial of hydroxyurea in infants (beginning at 9-18 months of age) with sickle cell anemia. An important secon
Autor:
Sheree L. Boulet, Scott D. Grosse, Suzette O. Oyeku, Bruce W. Thompson, Billie Fish, Scott T. Miller, Zhaoyu Luo, Winfred C. Wang
Publikováno v:
Blood. 118:171-171
Abstract 171 Background: The BABY HUG trial was a multi-center double-blinded randomized comparison of hydroxyurea (HU) versus placebo in infants (mean age 13.6 mo. at entry) with HbSS/Sβ° thalassemia who were followed for 2 years [Lancet 377(2011)
Autor:
Scott T. Miller, Zora R. Rogers, James F. Casella, Winfred C. Wang, Lori Luchtman-Jones, Rathi V. Iyer, Russell E. Ware, Sohail Rana, Bruce W. Thompson, Courtney D. Thornburg
Publikováno v:
Blood. 118:2134-2134
Abstract 2134 BABY HUG randomly assigned children with sickle cell anemia ages 9 to 18 months at entry to a two-year double-masked treatment course of 20 mg/kg/d of hydroxyurea (HU) or placebo (PBO). The primary goal of this clinical trial was to det
Autor:
R. Clark Brown, Zora R. Rogers, Ming Lu, Winfred C. Wang, Scott T. Miller, Rathi V. Iyer, James F. Casella, Thomas H. Howard, Jeffrey D. Lebensburger
Publikováno v:
Blood. 116:1631-1631
Abstract 1631 Introduction: Infants with sickle cell anemia (SCA) are at risk for organ damage and clinical events. Risk may vary depending on steady state hemoglobin level. BABY HUG (ClinicalTrials.org, NCT00006400), a NHLBI-NICHD supported phase II
Autor:
Cathie Snyder, Clinton H. Joiner, Zora R. Rogers, Karen Kesler, Carlo Brugnara, Winfred C. Wang, Karen Kalinyak, Martin H. Steinberg, Julie McAfee, Marilyn J. Telen, Lynn W. Wynn
Publikováno v:
Blood. 114:819-819
Abstract 819 Background. HbSC is characterized by increased red cell density and clinical complications but has rarely been the target of therapeutic trials. The CHAMPS Trial was a prospective, randomized, double-blinded, multi-center Phase II study
Autor:
Frans A. Kuypers, Yamaja Setty, Suba Krishnan, George R. Buchanan, Karen Kesler, Lori Styles, Marie J. Stuart, Charles T. Quinn, Theodore Wun, Kenneth I. Ataga, Nigel S. Key, Winfred C. Wang, Kim Smith-Whitley, Seungshin Rhee
Publikováno v:
Blood. 114:1515-1515
Abstract 1515 Poster Board I-538 BACKGROUND Acute chest syndrome (ACS) is a common cause of morbidity and mortality for individuals with sickle cell disease (SCD). The treatment of ACS is mainly supportive. Prior studies have shown that intravenous p
Autor:
Russell E. Ware, Renee C. Rees, Rathi V. Iyer, Scott T. Miller, Peter A. Lane, Winfred C. Wang, Sohail Rana
Publikováno v:
Blood. 112:1413-1413
A urine concentrating defect is quite common in sickle cell anemia (SCA), has its onset in early childhood, and may be reversible (with transfusion) until age 10 years. BABY HUG is an NHLBI-NICHD sponsored double-blind, placebo-controlled Phase III C
Autor:
Robert J. Adams, Russell E. Ware, Judy Luden, Stuart Toledano, Sherri A. Zimmerman, Clark Brown, Duane Bonds, Zora R. Rogers, Renee C. Rees, Scott T. Miller, Caterina P. Minniti, James F. Casella, Li Daner, Sohail Rana, Winfred C. Wang, Rathi V. Iyer, Julio C. Barredo, A. Russell Gerber
Publikováno v:
Blood. 106:952-952
Transcranial Doppler (TCD) is useful in children with sickle cell anemia (SCA) to detect increased risk of stroke. The use of TCD in infants less than 2 years of age is less well established, but has previously been shown to be feasible. As a seconda